SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp after-hours QQQ drop following the FAAs nationwide ground stop dominated discussion, with traders debating whether the communications outage was a technical failure or a cyberattack; the latter remains speculation. This came amid existing pressure on tech and AI stocks tied to Nvidia-related uncertainty, while traders were split between expecting further declines and buying the dip.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebiuss post-earnings selloff is being tied to delays in bringing third-party data-center capacity online, which shift expected revenue into a later period and raise execution concerns; traders also cite Nvidia-related turmoil and weakness across AI and neocloud stocks as amplifiers. The community is split between dip buyers who see long-term AI-cloud demand as intact and bears focused on delivery risks, heavy investment, and continued downside.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

A nationwide FAA ground stop tied to an air-traffic-control communications issue has put Delta and other airlines in focus. Traders flag possible operational pressure, while some note the stocks muted reaction; speculation about an AI or cyber cause remains unconfirmed.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Traders are focused on the FDAs PDUFA decision for ivonescimab plus chemotherapy in EGFR-mutated lung cancer, with approval versus a possible CRL the dominant debate. Bulls point to the trials PFS benefit and favorable updated survival trend, while bears emphasize that the FDA has said statistically significant overall-survival evidence is needed; the uncertainty is driving binary-event positioning and volatile trading.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

The FAAs nationwide ground stop, attributed to an air-traffic-control communications failure, is drawing attention to UAL and other airlines. Traders are weighing the disruption and share-price pressure, while some speculate about AI or a cyberattack; neither cause has been confirmed.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

A nationwide FAA ground stop following an air-traffic-control communications failure is drawing attention to AAL and other airlines, with traders reacting to halted departures, flight delays, and pressure on airline shares. Speculation about a cyberattack appears in the discussion, but the cause has not been confirmed.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is drawing attention after a sharp decline amid a broader selloff in speculative and small-cap stocks; traders also point to stop-loss selling and short pressure, though those explanations are unverified. The drop has renewed debate over why the shares are weak despite favorable lonvo-z HAE data and an FDA priority review, with the FDA decision targeted for March 2027.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL immunotherapy data in colorectal cancer and progress toward the Phase 3 ROBBIN trial dominate discussion, with supporters highlighting encouraging early responses and potential broader use. Skeptics argue the small, nonrandomized studies still need confirmation and point to execution, financing, and dilution concerns.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

A nationwide FAA ground stop following an air-traffic-control communications issue has traders speculating about a possible cyber connection and whether cybersecurity stocks could benefit. A cyberattack has not been confirmed, and some traders question whether the outage should move CRWD at all.

Autonomi (ANT) is a cryptocurrency launched in 2025and operates on the Arbitrum platform. Autonomi has a current supply of 1,200,000,000 with 346,331,579 in circulation. The last known price of Autonomi is 0.0311505 USD and is down -0.06 over the last 24 hours. It is currently trading on 15 active market(s) with $124,825.83 traded over the last 24 hours. More information can be found at https://autonomi.com.

Aragon

Most attention reflects confusion between Aragons ANT token and Anthropics IPO, with many posts tagging Aragons ticker while discussing the unrelated listing. Aragon-specific discussion mentions its completed token redemption and project dissolution, alongside scattered governance updates and speculative trading.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining in pre-market trading.read more...

Why Did TRAW Stock Slump 28% After Hours?

Equity

Traws is delaying a planned human study of its lead flu treatment, tivoxavir marboxil, after feedback from a UK regulator.

Do Not Ignore this Rally

The market is currently witnessing a rare phenomenon: a synchronized breakout across the small-cap and emerging growth sectors. While mega-cap tech grabs the headlines, the real alpha is being generated by innovators in energy, space, and biotech. As we head into the closing bell and the crucial after-hours session, momentum is building in names that are fundamentally shifting their industries. $INTC, $RXT, $BB, $TRAW, $XERI, $RDW

A Hantavirus Update Has Sent This Nano-Cap Biotech Stock Surging Today – Here’s Why Retail Sees Potential 20x Gains

Traws Pharma, which develops antiviral drugs, said it plans to advance potential clinical candidates for the treatment of hantavirus infections.

Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment?

The company announced the completion of enrollment in its Phase 2 trial of Ratutrelvir, an investigational oral antiviral for mild-to-moderate COVID-19.

Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid

Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 patients.read more...

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials ChemDiv Extends CMC Services Collaboration for...

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. Dover...

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Reported GAAP EPS of -$0.16 down -45.45% YoY

Traws Pharma faces significant challenges including a clinical hold on its lead program, absence of revenue, and potential future liquidity constraints necessitating additional financing to support operations beyond early 2027.

Traws Pharma is progressing its lead influenza candidate toward MHRA resubmission while securing potential financing of up to $50 million and expanding its platform capabilities into other emerging viral threats.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Traws Pharma Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>The company emphasized that it maintains a portfolio of backup influenza antiviral compounds and is actively advancing alternative candidates.</li><li>The Food and Drug Administration placed the company’s Investigational New Drug (IND) application for tivoxavir marboxil earlier this year.&nbsp;</li><li>According to data from Koyfin, both the analysts covering TRAW rate it a ‘Buy.’</li></ul>Shares of Traws Pharma (TRAW) fell about 28% in after-hours trading on Friday after the company said it is delaying a key study for its experimental flu drug.The company announced it is putting off a planned human study for its lead flu treatment, tivoxavir marboxil, after receiving feedback from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).Under the trial, slated to begin this quarter, healthy volunteers would have received either the drug or a placebo and then been exposed to a controlled strain of the influenza virus. Researchers would then gauge whether the drug prevented an infection.<h2 class="st-heading-2">Traws Still Sees Strong Potential For Bird Flu Treatment</h2>Traws said it is stepping back from the study for now while it works on addressing the regulators’ concerns. The company still believes the drug has potential, especially for treating or preventing serious bird flu infections.“Tivoxavir marboxil demonstrated potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile consistent with its use for bird flu treatment and prevention,” said the company’s Chief Science Officer, David Pauza. “The product candidate retains potential for emergency use in a bird flu outbreak and for prevention in high-risk populations.”The company emphasized that it maintains a portfolio of backup influenza antiviral compounds and is actively advancing alternative candidates. The company has a cash runway extending into the first quarter of 2027.“While we have had a setback in the development of our lead compound for influenza, the program continues to be a high priority,” said Chief Medical Officer Robert R. Redfield.<h2 class="st-heading-2">U.S. Clinical Trials Also On Hold</h2>Meanwhile, clinical trials of the drug are also on hold in the U.S. The Food and Drug Administration placed the company’s Investigational New Drug (IND) application for tivoxavir marboxil on hold shortly after Traws filed it in mid-January. The hold stems from concerns about the toxicology data package, particularly around the potential to cause genetic changes.In February, the company said it was preparing a response to address the regulator’s concerns, without which it cannot commence clinical trials.<h2 class="st-heading-2">How Did TRAW Retail Traders React?</h2>On Stocktwits, retail sentiment around TRAW rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume improved from ‘extremely low’ to ‘low’ levels.A Stocktwits user dismissed the after-hours drop as “overblown.”<stembedurl>https://www.stocktwits.com/AshleySchaeffer_BMW/message/656347866</stembedurl>According to data from Koyfin, both the analysts covering TRAW rate it a ‘Buy.’ The stock has an average 12-month price target of $5.5, implying a potential upside of over 300% from the stock’s last close.<a href="https://stocktwits.com/symbol/TRAW">TRAW stock</a> has fallen 4% this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dnth-stock-clocks-best-day-in-over-3-months-on-strong-nerve-disorder-study-results/cZKd9QHR75h">DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of biopharma company Traws Pharma Inc. is displayed on a smartphone in front of abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

Vanguard Extended Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$TRAW The fact that this company continues to find investors at all is unbelievable.  They have gone to zero over and over and over and over again.  Incoming zero through the reverse split now too.  Unbelievable.

Roger Moore

$TRAW 💰 

On October 23, 2026, Traws Pharma, Inc. entered into a common stock purchase agreement with Roth Principal Investments, LLC, granting Traws the right to sell up to $50,000,000 of newly issued common stock under a related registration rights agreement. 

Prioritized by relevance

Feed

News

Sentiment

Earnings

Fundamentals

Info

TRAW Traws Pharma Inc.

Fundamentals

Latest TRAW News